Phase 2a clinical trial describes safety and efficacy of dendrimer nanotherapy in severe COVID-19 patients

By | July 21, 2022
A multicenter, randomized, placebo-controlled phase 2a clinical trial has recently been conducted to evaluate the efficacy of a nanotherapeutic compound OP-101 in treating severe COVID-19 patients.